Press "Enter" to skip to content

Posts published in “Guest Content”

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study


This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2018; 361 under…

Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets


This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…

Celgene vs. Dr. Reddy’s Revlimid patent infringement case depends on polymorph stability; lack thereof may favor Celgene position – experts


This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…

Do NOT follow this link or you will be banned from the site!